L
Leslie Citrome
Researcher at New York Medical College
Publications - 525
Citations - 15866
Leslie Citrome is an academic researcher from New York Medical College. The author has contributed to research in topics: Antipsychotic & Olanzapine. The author has an hindex of 59, co-authored 489 publications receiving 14034 citations. Previous affiliations of Leslie Citrome include Nathan Kline Institute for Psychiatric Research & Manhattan Psychiatric Center.
Papers
More filters
Journal ArticleDOI
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
Oliver D. Howes,Robert A. McCutcheon,Ofer Agid,Andrea de Bartolomeis,Nico J.M. van Beveren,Michael L. Birnbaum,Michael A P Bloomfield,Rodrigo A. Bressan,Robert W. Buchanan,William T. Carpenter,David J. Castle,Leslie Citrome,Zafiris J. Daskalakis,Michael Davidson,Richard J. Drake,Serdar M. Dursun,Bjørn H Ebdrup,Helio Elkis,Peter Falkai,W. Wolfgang Fleischacker,Ary Gadelha,Fiona Gaughran,B. Glenthøj,Ariel Graff-Guerrero,Jaime Eduardo Cecílio Hallak,William G. Honer,James L. Kennedy,Bruce J. Kinon,Stephen M. Lawrie,Jimmy Lee,F. Markus Leweke,James H. MacCabe,Carolyn B. McNabb,Herbert Y. Meltzer,Hans-Jürgen Möller,Shinchiro Nakajima,Christos Pantelis,Tiago Reis Marques,Gary Remington,Susan L. Rossell,Bruce R. Russell,Cynthia Siu,Takefumi Suzuki,Iris E. C. Sommer,David Taylor,Neil Thomas,Alp Üçok,Daniel Umbricht,James T.R. Walters,John M. Kane,Christoph U. Correll +50 more
TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.
Journal ArticleDOI
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
Robert M. Bilder,Robert Goldman,Jan Volavka,Pál Czobor,Matthew J. Hoptman,Brian Sheitman,Jean Pierre Lindenmayer,Leslie Citrome,Joseph P. McEvoy,Michal Kunz,Miranda Chakos,Thomas B. Cooper,Terri L. Horowitz,Jeffrey A. Lieberman +13 more
TL;DR: Patients with a history of suboptimal response to conventional treatments may show cognitive benefits from newer antipsychotic drugs, and there may be differences between atypical antipsychotics drugs in their patterns of cognitive effects.
Journal ArticleDOI
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Jean Pierre Lindenmayer,Pál Czobor,Jan Volavka,Leslie Citrome,Brian B. Sheitman,Joseph P. McEvoy,Thomas B. Cooper,Miranda Chakos,Jeffrey A. Lieberman +8 more
TL;DR: In this prospective randomized trial, clozAPine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanZapine were associatedWith an increase in cholesterol levels.
Journal ArticleDOI
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder
Jan Volavka,Pál Czobor,Brian Sheitman,Jean Pierre Lindenmayer,Leslie Citrome,Joseph P. McEvoy,Thomas B. Cooper,Miranda Chakos,Jeffrey A. Lieberman +8 more
TL;DR: Improvements seen in total and negative symptom scores with clozapine and olanzapine were superior to haloperidol and the effects of atypical antipsychotics in this population were statistically significant.
Journal ArticleDOI
Neurocognitive correlates of the COMT Val158Met polymorphism in chronic schizophrenia
Robert M. Bilder,Jan Volavka,Pál Czobor,Anil K. Malhotra,James L. Kennedy,Xingqun Ni,Robert Goldman,Matthew J. Hoptman,Brian Sheitman,Jean-Pierre Lindenmayer,Leslie Citrome,Joseph P. McEvoy,Michal Kunz,Miranda Chakos,Thomas B. Cooper,Jeffrey A. Lieberman +15 more
TL;DR: The findings provide independent support for the hypothesis that the catechol-O-methyltransferase Val(158)Met polymorphism influences neurocognitive function in schizophrenia, and suggest that the functional effects may be expressed on measures of Processing Speed and Attention.